DAWN

Day One Biopharmaceuticals, Inc. (DAWN) | Rumor.io

Day One Biopharmaceuticals

DAWN

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)94%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about DAWN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Mar 10

$DAWN +100% after being acquired at an 89% premium, with cancer drug biotech agreeing to the deal.
The acquisition may have a positive impact on the biotech M&A environment, with a strategic power play for rare oncology.
The stock price is expected to hold around $21.30, with buyers and sellers not budging from this level.

Generated by AI

Sentiment

Of the messages about DAWN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	90.2% +1.31
Bearish	—	—	—	9.8% -1.31

Bullish· Mar 6

$DAWN's buyout success story highlights the importance of patience and holding onto concentrated positions, which can lead to significant gains.
The company's acquisition demonstrates its potential for growth and the value of its pipeline, with a BLA coming up, indicating a promising future.
$DAWN's impressive momentum, with a +65% surge before most desks finish coffee, shows its potential for strong short-term performance, making it an attractive option for investors.

Bearish· Apr 25

$DAWN's price dropped significantly after approval, from $17.5 to $13, despite analysts raising their price targets to $30s.
The stock's market capitalization of $700M, net of cash, with an approved drug and likely additional uses, does not justify its current price.
The company's poor price action after approval is a repeat of what happened with IOVA, which tanked after approval before running up.

Generated by AI

Topics

Of the messages about DAWN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	0%	5.69%
Announcements	—	—	0%	77.06%
Controversies	—	—	0%	0.34%
Earnings	—	—	0%	2.7%
Macro	—	—	0%	0.98%
Technical Analysis	—	—	100%	13.22%

Announcements· Mar 7

Servier is set to acquire Day One Biopharmaceuticals' $DAWN shares for $21.50 each in cash, valuing the deal at $2.5 billion.
The acquisition is expected to add pediatric brain cancer drug Ojemda to Servier's portfolio, strengthening its rare-cancer pipeline.
Analysts are speculating about potential higher bids, special dividends, or legal noise related to the investigation into the board's fiduciary duty and sales process.

Technical Analysis· Jun 13

$DAWN is expected to retest the $6.62 level as it needs a gap fill down to previous close and company filed S3 for offering.
$DAWN is considered overbought and algos will bring it down, with some traders expecting a rug pull as selling pressure mounts.
$DAWN is in an uptrend since the momentum indicator exceeded the 0 level on June 9, 2022, but it has run into the SMA200 on the daily chart at $16.

Generated by AI

Community

Of the messages about DAWN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	0%	60.55%
Newcomers	—	—	100%	39.45%

Regulars· Mar 6

$DAWN was acquired by Servier in a $2.5B deal, expanding Servier's rare oncology portfolio.
The biotech's chart showed an orderly bearish-to-bullish reversal, with accumulation evident in the form of big green candles.
Holding $DAWN through its buyout was a winning strategy, with the asset doubling in value.

Newcomers· Mar 7

The Servier company is acquiring Day One Biopharmaceuticals' shares in a $2.5 billion cash deal, valuing each share at $21.50.
The acquisition adds Day One's oncology programs to Servier's rare-cancer pipeline, strengthening its position in pediatric low-grade glioma and other adult/pediatric cancers.
The deal has sparked a surge in Day One's stock price, with some analysts attributing the increase to a combination of factors, including a successful commercial launch and legal scrutiny from Brodsky & Smith.

Generated by AI

Also Discussed

Investors talking about DAWN also mention

#	Name	Attention
1	SWTX - SpringWorks Therapeutics, Inc.	——
2	Iovance Biotherapeutics Inc.IOVA	1.03%+0.91
3	X4 Pharmaceuticals, Inc.XFOR	0%0
4	Kura Oncology, Inc.KURA	0%+0
5	Aquestive Therapeutics Inc.AQST	0%+0
6	DICE - DICE Therapeutics, Inc.	——
7	NARI - Inari Medical, Inc.	——
8	Syndax Pharmaceuticals, Inc.SNDX	0%+0
9	Arcutis Biotherapeutics, Inc.ARQT	0%+0
10	Janux Therapeutics, Inc.JANX	0%0